Evidence map›Paper›PMID 41475844›Full record

ArticleJournal for immunotherapy of cancer2025

Mechanistic insights into PD-1 inhibitor-associated immune thrombocytopenia: a case report integrating longitudinal transcriptomic profiling.

Huishan Li, Yan Wang, Jianfeng Zhu, Hehui Chen, Tianshu Liu, Luoyan Ai

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Engineering the next generation of cellular therapies for solid tumors: multi-specific armored CARs and TME reprogramming strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  4. Review
  5. Review
  6. Conversion therapy using transarterial chemoembolization plus tislelizumab for unresectable hepatocellular carcinoma: effects on tumor necrosis and anti-tumor immune response.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Huishan LiDepartment of Medical Oncology, Zhongshan Hospital Fudan University, Shanghai, Shanghai, China.ORCID http://orcid.org/0009-0001-5583-2969
Yan WangDepartment of Medical Oncology, Zhongshan Hospital Fudan University, Shanghai, Shanghai, China.
Jianfeng ZhuDepartment of Laboratory Medicine, Zhongshan Hospital Fudan University, Shanghai, Shanghai, China.
Hehui ChenDepartment of Laboratory Medicine, Zhongshan Hospital Fudan University, Shanghai, Shanghai, China.
Tianshu LiuDepartment of Medical Oncology, Zhongshan Hospital Fudan University, Shanghai, Shanghai, China ai.luoyan@zs-hospital.sh.cn liu.tianshu@zs-hospital.sh.cn.
Luoyan AiDepartment of Medical Oncology, Zhongshan Hospital Fudan University, Shanghai, Shanghai, China ai.luoyan@zs-hospital.sh.cn liu.tianshu@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0002-1093-2018

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have significantly improved survival outcomes in patients with advanced malignancies. However, their association with immune thrombocytopenia (ITP) poses a critical risk of severe hemorrhage and necessitates treatment discontinuation. The precise molecular mechanisms underlying ICI-associated ITP remain largely unclear, critically impeding the development of predictive biomarkers and targeted therapeutic strategies. Here, we present a case report of an elderly patient with stage IV gastric adenocarcinoma who developed recurrent ITP following programmed death receptor-1 (PD-1) inhibitor serplulimab, trastuzumab and chemotherapy. Notably, longitudinal peripheral blood mononuclear cell samples were collected and subjected to transcriptomic profiling before and after two distinct ITP episodes: the initial occurrence and a recurrence triggered by PD-1 inhibitor rechallenge, providing matched time-resolved data for mechanistic analysis. Our findings demonstrate that ICIs-induced ITP involves a dual pathogenic mechanism combining immune-mediated platelet destruction and intrinsic megakaryopoietic impairment providing a novel conceptual framework for understanding this immunotherapy complication. And this represents the first prospective longitudinal investigation combining serial biospecimen collection with transcriptomic profiling (RNA sequencing) to elucidate mechanisms underlying ICIs-induced ITP.

Indexed as

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPurpura, Thrombocytopenic, IdiopathicStomach NeoplasmsAgedFemaleGene Expression ProfilingHumansLongitudinal StudiesMaleTranscriptomeImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorImmune related adverse event - irAEThrombocytopenia

Identifiers

PMID41475844
PMCPMC12766837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.